The Role of the Renin-Angiotensin-Aldosterone System in Cardiovascular Disease: Pathogenetic Insights and Clinical Implications

Abstract

Increased attention has been placed on the activation of the renin-angiotensin-aldosterone system (RAAS) and pathogenetic mechanisms in cardiovascular disease. Multiple studies have presented data to suggest that cardiac and arterial stiffness leading to adverse remodeling of both the heart and vasculature leads to the various pathological changes seen in coronary artery disease, heart failure (with preserved and reduced ejection fractions), hypertension and renal disease. Over-activation of the RAAS is felt to contribute to these structural and endocrinological changes through its control of the Na+/K+ balance, fluid volume, and hemodynamic stability. Subsequently, along these lines, multiple large investigations have shown that RAAS blockade contributes to prevention of both cardiovascular and renal disease. We aim to highlight the known role of the activated RAAS and provide an updated description of the mechanisms by which activation of RAAS promotes and leads to the pathogenesis of cardiovascular disease.

Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors

“…ACE Inhibitors (ACEIs), Angiotensin Receptor Blocker (ARBs), Calcium Channel Blocker (CCBs), and Thiazides-Type Diuretics (TTDs) 11 . Experimental evidence suggests ACEIs and/or ARBs are crucial for preventing and managing CVD, with JNC8 guidelines suggesting preferred classes of drugs like ACEIs and Neprilysin Inhibitor 12 – 14 . ACE which catalyzes the conversion of angiotensin-I to angiotensin-II is a membrane-bound dipeptidyl carboxyl peptidase that has two important active sites viz.…”

Life‐threatening bronchospasm induced by an angiotensin‐converting enzyme inhibitor in a chronically ventilated patient: Diagnostic pitfalls and literature review

“…Introducing angiotensin‐converting‐enzyme inhibitors (ACEi) and angiotensin II‐AT1‐receptor blockers (ARBs) attenuates hypertension and provides substantial cardio‐renal protection with reduced mortality 1–4 . This reflects the suppression of the ‘pressor’ renin/angII/AT1R/aldosterone axis, which, in addition to vasoconstriction, stimulates inflammation, fibrosis, hypercoagulation, and apoptosis, generating hypertension and progressive vascular, myocardial, and renal injury.…”

“…Introducing angiotensin‐converting‐enzyme inhibitors (ACEi) and angiotensin II‐AT1‐receptor blockers (ARBs) attenuates hypertension and provides substantial cardio‐renal protection with reduced mortality. 1 , 2 , 3 , 4 This reflects the suppression of the ‘pressor’ renin/angII/AT1R/aldosterone axis, which, in addition to vasoconstriction, stimulates inflammation, fibrosis, hypercoagulation, and apoptosis, generating hypertension and progressive vascular, myocardial, and renal injury. Blocking this harmful axis diverts the angiotensinogen‐derived system towards the ‘depressor’ ACE‐2/ang‐(1–7)/MasR axis that counterbalances the injurious pressor axis, exerting vasodilation and inhibiting inflammation, hypercoagulation, apoptosis, and fibrosis.…”

Renal safety and survival among acutely ill hospitalized patients treated by blockers of the Renin-Angiotensin axis or loop diuretics: a single-center retrospective analysis

“…The renin-angiotensin-aldosterone system (RAS) plays a central role in human diseases, promoting vasoconstriction and fibrosis. Its inhibition by angiotensin-converting enzyme inhibitors (ACEi) and angiotensin-AT1-receptor blockers (ARBs) or through the interference with aldosterone action revolutionized the management of cardiovascular and renal disorders [ 1 , 2 ]. ACEi and ARBs attenuate the progression of chronic kidney disease (CKD) [ 3 , 4 ].…”